Trials / Completed
CompletedNCT01957579
A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI-551 | MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle |
Timeline
- Start date
- 2011-05-25
- Primary completion
- 2015-09-15
- Completion
- 2015-09-15
- First posted
- 2013-10-08
- Last updated
- 2017-06-12
- Results posted
- 2017-04-10
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01957579. Inclusion in this directory is not an endorsement.